Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
Titel:
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
Auteur:
Liu, J.F. Moore, K.N. Birrer, M.J. Berlin, S. Matulonis, U.A. Infante, J.R. Wolpin, B. Poon, K.A. Firestein, R. Xu, J. Kahn, R. Wang, Y. Wood, K. Darbonne, W.C. Lackner, M.R. Kelley, S.K. Lu, X. Choi, Y.J. Maslyar, D. Humke, E.W. Burris, H.A.